干细胞用于治疗性新生血管进展：未来治疗“无细胞”？

sunsong7

8 q: G# T" L, V3 z% w5 b# h8 V( Q

3 k9 S; l9 O# L  K1 p1 y子曰：上善若水 大成若缺——干细胞治疗的终极解决方案将是不移植外源干细胞！
9 G" k" j! {9 b9 G. x) C  }: @, p" a/ a, K0 s: T6 n
替LZ把摘要贴出来
* t% ?% G& {- H9 a2 j& N4 J1 ?Current developments in the use of stem cell for therapeutic neovascularisation: is the future therapy “cell-free”?6 c5 Y# b* u- q! o/ f& O2 @  l
3 d( T  \& r0 o( ]8 b4 O
The plasticity and self-regenerative properties of stem cells have opened new avenues in regenerative medicine. Greater understanding of the biology of stem cells is followed by growing expectations of a rapid translation into alternative therapeutic options. Recent preclinical studies and clinical trials employing stem and progenitor cells from different sources have shown encouraging results. However, their underlying mechanisms are still poorly understood, the potential adverse effects and the discrepancy in efficacy remain to be further investigated.
" C# r/ y. D6 f- }6 {+ B7 E& qTheir essential role in vessel regeneration has made endothelial progenitor cells (EPC) a suitable candidate for therapeutic applications aiming at tissue revascularisation. Recent evidence suggests that EPC contribute to neovascularisation not only by direct participation in tissue homeostasis but mainly via paracrine mechanisms. In future, novel therapeutic strategies could be based on EPC paracrine factors or synthetic factors, and replace cell transplantation.
4 F" E$ q, X: Z( [; V- s

sunsong7

再生医学骨髓干细胞源旁分泌因子现状和治疗潜力  http://www.stemcell8.cn/forum-vi ... FA%D2%BD%D1%A7.html